Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 6/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | CPT1A | P50416 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29688274 | 1.00 | NR4A2 (0.47) | NR4A2CYP3A4CYP2C19NAMPTCREBBP | |
| SCHEMBL1763120 | 0.88 | CYP2D6 (0.45) | NR4A2CYP2C19CREBBPHASPINALOX5 | |
| SCHEMBL10183822 | 0.85 | GABRA1 (0.45) | CYP3A4CYP2C19NAMPTHASPIN | |
| SCHEMBL369404 | 0.81 | CYP2C19 (0.48) | NR4A2CYP3A4CYP2C19NAMPTHASPIN | |
| Potassium Ion SCHEMBL3887398 | 0.80 | NAMPT (0.47) | NR4A2CYP3A4CYP2C19NAMPTHASPIN | |
| SCHEMBL3887392 | 0.80 | HTR6 (0.46) | NR4A2CYP3A4CYP2C19NAMPTHASPIN | |
| SCHEMBL12481581 | 0.80 | HASPIN (0.64) | NR4A2CYP3A4CYP2C19NAMPTCREBBP | |
| SCHEMBL2817519 | 0.79 | NAMPT (0.51) | NR4A2CYP3A4CYP2C19NAMPTHASPIN | |
| SCHEMBL30658176 | 0.78 | NR4A2 (0.71) | NR4A2CREBBPALOX5RAB9A | |
| SCHEMBL729076 | 0.78 | NR4A2 (0.71) | NR4A2CREBBPALOX5RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11369624-B2 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | VIIV HEALTHCARE UK (NO. 4) LIMITED | 2022-06-28 | — | — | US | disclosed |
| US-20210023098-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2021-01-28 | — | — | US | disclosed |
| US-20200046743-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2020-02-13 | — | — | US | disclosed |
| US-20190111066-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2019-04-18 | — | — | US | disclosed |
| US-20180000849-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK (NO 4) LTD (GB) | 2018-01-04 | — | — | US | disclosed |
| US-20160361328-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK (NO 4) LTD (GB) | 2016-12-15 | — | — | US | disclosed |
| US-20160361328-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK (NO 4) LTD (GB) | 2016-12-15 | — | — | US | disclosed |
| US-20150315218-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-11-05 | — | — | US | disclosed |
| US-20150232414-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
| US-20150232414-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
| EP-1725569-B1 | PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2008-01-23 | — | — | EP | disclosed |
| US-7297705-B2 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-11-20 | — | — | US | disclosed |
| US-7297705-B2 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-11-20 | — | — | US | disclosed |
| US-7297705-B2 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-11-20 | — | — | US | disclosed |
| US-20050209246-A1 | Prodrugs of piperazine and substituted piperidine antiviral agents | SALZUFER HOLDING INC., AS ADMINISTRATIVE AGENT | 2005-09-22 | — | — | US | disclosed |
| US-20050020598-A1 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-01-27 | — | — | US | disclosed |
| WO-2004094422-A1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-11-04 | — | — | WO | disclosed |
| US-6800640-B2 | ANTISEROTONINE AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS | WYETH | 2004-10-05 | — | — | US | disclosed |
| US-20030181463-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2003-09-25 | — | — | US | disclosed |
| US-20030171395-A1 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000849-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | NR4A2 2697/4885CYP3A4 1322/4885CYP2C19 435/4885 |
| US-20150315218-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | ZC3HAV1L, CCR5, CCRL2 | NR4A2 2726/4885CYP3A4 1585/4885CYP2C19 631/4885 |
| US-20190111066-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | NR4A2 2697/4885CYP3A4 1322/4885CYP2C19 435/4885 |
| US-20150232414-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | NR4A2 2697/4885CYP3A4 1322/4885CYP2C19 435/4885 |
| US-20050209246-A1 | Prodrugs of piperazine and substituted piperidine antiviral agents | ZC3HAV1L, CCR5, CCRL2 | NR4A2 1952/4885CYP3A4 1230/4885CYP2C19 470/4885 |
| US-20030171395-A1 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1A | NR4A2 882/4885CYP3A4 930/4885CYP2C19 513/4885 |
| US-20210023098-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | ZC3HAV1L, CCR5, CCRL2 | NR4A2 2452/4885CYP3A4 1334/4885CYP2C19 402/4885 |
| US-20050020598-A1 | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR7 | NR4A2 936/4885CYP3A4 909/4885CYP2C19 499/4885 |
| US-11369624-B2 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | CCR5, ZC3HAV1L, CCRL2 | NR4A2 2697/4885CYP3A4 1322/4885CYP2C19 435/4885 |
| US-20200046743-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | NR4A2 2697/4885CYP3A4 1322/4885CYP2C19 435/4885 |
| US-20160361328-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | NR4A2 2697/4885CYP3A4 1322/4885CYP2C19 435/4885 |
| US-20030181463-A1 | Antiviral azaindole derivatives | ZC3HAV1, MAVS, AZI2 | NR4A2 1214/4885CYP3A4 491/4885CYP2C19 3101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.